GlobeNewswire by notified

HMNC Brain Health to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference

Share

MUNICH, Germany, Dec. 01, 2021 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a clinical stage biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, announced today that Chief Executive Officer, Benedikt von Braunmühl, Chief Clinical Development Officer, Dr. Hans Eriksson and Head of Operations, Dr. Maximilian Döbler will present at H.C. Wainwright’s 2nd Annual Psychedelics Conference on Monday, December 6th, 2021.

In addition, Dr. Eriksson will participate in the ‘Future of Mental Healthcare’ panel at 2:30 p.m. Eastern Time. To attend, please register here.

HMNC Brain Health’s virtual presentation will be available beginning Monday, December 6th at 7:00 a.m. Eastern Time and is accessible through the following webcast link: https://journey.ct.events/view/d77f2d7d-bff2-4d9a-8e89-620a24d1f35a.

A webcast of the presentation will be available on the HMNC Brain Health Website for 90 days through the above webcast link.

HMNC Brain Health’s management team will also participate in virtual one-on-one meetings over the duration of the conference. To schedule a meeting, please contact your H.C. Wainwright representative or KCSA Strategic Communications at HMNCBrain@kcsa.com.

About HMNC Brain Health

HMNC Brain Health (HMNC Holding GmbH) is a biotech company pioneering in developing personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission. The company develops a unique pipeline for targeting both major depressive disorder (MDD) and treatment-resistant depression (TRD). HMNC Brain Health is located at one of the leading European biotech hubs in Munich and backed by renowned family offices. The company now enters the next stage of its development with a large-scale licensing and fundraising agenda.

Media Contacts
Alexander Schmidt (Europe)
+49 151 22 99 39 765
alexander.schmidt@gaulyadvisors.com

Anne Donohoe (U.S.)
+1 212-896-1265
hmnc@kcsa.com

Investor Contact (U.S.)
Tim Regan
+1 347-487-6788
tregan@kcsa.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Cover the Latest Developments in Allergy and Clinical Immunology at the EAACI Congress 2024 in Valencia, Spain19.3.2024 12:42:20 CET | Press release

https://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 VALENCIA, Spain, March 19, 2024 (GLOBE NEWSWIRE) -- The European Academy of Allergy and Clinical Immunology (EAACI), with a membership of over 16,000 from 125 countries, annually orchestrates its congress to unveil the latest research and innovative advancements in allergy and clinical immunology. We are thrilled to extend a warm invitation to you for the upcoming EAACI Congress 2024, scheduled to take place in Valencia from May 31st to June 3rd, 2024. In a bid to provide you with an immersive experience, we will offer you a dedicated press area where you can schedule interviews with leading physicians and researchers in the field. Register for free LOCATION: Our venue, Feria de Valencia, is a prestigious convention and exhibition centre known for its modernity and versatility. Moreover, the event will take place at the vibrant city of Valencia, which is celebrated for its harmonious coexistence of

Notice of the Annual General Meeting 2024 of Copenhagen Airports A/S19.3.2024 12:42:03 CET | Press release

Notice is hereby given of the Annual General Meeting of Copenhagen Airports A/S to be held on Tuesday, 16 April 2024 at 3:00 pm. The notice, including the agenda and the full text of the proposed resolutions is attached. COPENHAGEN AIRPORTS A/S P.O. Box 74 Lufthavnsboulevarden 6 DK-2770 Kastrup Telephone: +45 32313231 E-mail: cphpresse@cph.dk www.cph.dk CVR no. 14 70 72 04 Attachment Copenhagen Airports A_S - AGM Notice 2024

Indkaldelse til ordinær generalforsamling 2024 i Københavns Lufthavne A/S19.3.2024 12:42:03 CET | pressemeddelelse

Der indkaldes hermed til ordinær generalforsamling i Københavns Lufthavne A/S tirsdag den 16. april 2024 kl. 15.00. Indkaldelsen med dagsordenen og fuldstændige forslag er vedhæftet. KØBENHAVNS LUFTHAVNE A/S P.O. Box 74 Lufthavnsboulevarden 6 2770 Kastrup Telefon: 32313231 E-mail: cphpresse@cph.dk www.cph.dk CVR nr. 14 70 72 04 Vedhæftet fil Københavns Lufthavne A_S - OGF Indkaldelse 2024

Brookfield Asset Management Completes Annual Filings and Announces Management Changes19.3.2024 12:30:00 CET | Press release

BROOKFIELD, NEWS, March 19, 2024 (GLOBE NEWSWIRE) -- Brookfield Asset Management Ltd. (NYSE: BAM, TSX: BAM) announced that it has filed its 2023 annual materials on Form 40-F, including its audited financial statements and management’s discussion and analysis for the year ended December 31, 2023, with the SEC on EDGAR as well as with the Canadian securities authorities on SEDAR. These documents are also available at www.bam.brookfield.com and a hardcopy will be provided to shareholders free of charge upon request. Appointment of Hadley Peer Marshall as Chief Financial Officer The Board of Brookfield Asset Management is pleased to announce the appointment of Hadley Peer Marshall as Chief Financial Officer, effective May 31, 2024. Ms. Peer Marshall joined Brookfield in New York in 2015 in the Infrastructure Group where she is co-head of infrastructure debt and structured solutions. Ms. Peer Marshall has over 20 years of experience in asset management and business leadership, including in

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform19.3.2024 12:30:00 CET | Press release

The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologiesAI-Immunology™ outcompetes standard vaccine target discovery approaches and holds the promise of addressing serious unmet needsWith a unique modular architecture, AI-Immunology™ is scalable and adaptable towards partner needsThe potential of AI-Immunology™ is validated by established partnerships, including an ongoing vaccine collaboration with MSD COPENHAGEN, Denmark, March 19, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today hosts a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform. The event will be hosted at our facilities in Hørsholm, Denmark, between 14.00 – 18.00 CET / 9.00 a.m. - 1.00 p.m. EST and can be accessed remotely here. The R&D Day featu

HiddenA line styled icon from Orion Icon Library.Eye